Tech
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the full discussion on TechCrunch
This article was aggregated from TechCrunch. Click to join the conversation.
View on TechCrunch
Related Trends in Tech
UBS’s $20 Million AML Fine Exposes a Blind Spot in Automated Monitoring
Upwind Acquires AI Security Startup Aegis, Launches AI Security Labs
George Santos Settled With the CFTC but Kalshi Wasn’t Finished
Building a Type-Safe Database Workflow With Kysely
The TechBeat: The Embarrassing Rise of Vibe Lawyering (9/23/2026)
AWS Cost Optimization: 5 Ways to Find and Cut Waste